III.             VIII. REFERENCES

1) Searle A. The use of metal colloids in health and disease. EP Sutton. New York 1919, pg 75.

2) Michaelis L. The effect of ions in colloidal systems. Williams Wilkins, Baltimore 1925.

3) New and Unofficial Remedies. Editor, American Medical Association Advisory Panel. Lippincott
Publications, Philadelphia 1950, p 100.

4) Goodman L, Gelman A. The pharmacological basis of therapeutics.
5th Edition, MacMillion New York 1975, pg 930.

5) Sommonetti N: Electro chemical Ag+ for preservation use. Applied and Experimental Biology.
Amer Society of Microbiology, Wash DC 1992, p 3834.

6) Monafo W, Moyer C. The treatment of extensive thermal burns with 0.5% silver nitrate solution in early treatment of severe burns. Ann NY Acad Sci 1968: 150; 937.

7) Fox C: Silver sulphadrazine-a new topical therapy for pseudomonas in burns. Arch Surg 1968:96; 184.

8) Bador K: Organ deposition of silver following silver nitrate therapy for burns. PRS 1966:37; 550.

9) Lansdocon A: Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicology 1995:25; 397-462.

10) Marshall J, Schneider R: Systemic argyria secondary to silver nitrate. Arch Derm 1977:113-177.

11) Toxicology and biological monitoring of metals in humans. Ed Carson B, Lunes Path 1986: p 100.

12) Lockart S: Topical silver sulphadiazine: side effects and urinary excretion. Burns 1983:10; 9.

13) Jarrett F, Demling R: Acute leucopenia during topical burn therapy with silver sulphadiazine.
Am J Surg 1978:135; 818.

14) Scientific Background 14. Release of silver from Acticoat burn dressing.
Exeter, New Hampshire, USA: Westaim Biomedical Inc.; 1999.

15) Wan AT, Conyers RA, Coombs CJ, Masterton JP. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem 1991:37(10 Pt 1); 1683-7.

16) Boosalis MG, McCall JT, Ahrenholz DH, Solem LD, McClain CJ. Serum and urinary silver levels in thermal injury patients. Surgery 1987:101(1); 40-3.

17) Kaye ET, Kaye KM. Topical antibacterial agents. Infect Dis Clin North Am 1995:9(3); 547-59.

18) Ward RS, Saffle JR. Topical agents in burn and wound care. Phys Ther 1995:75(6); 526-38.

19) Tredget EE. The effects of a silver metal coated dressing on a porcine wound. Edmonton,
Alberta, Canada: University of Alberta; 1995: Report No.: #215/09/95

20) Smoote E, Kucan J, Roth A., et.al. In vitro toxicity testing for antimicrobials against human
keratinocytes. Plast Reconstr Surg 1991:57; 917-924.

21) Demling RH, DeSanti L. The role of silver in wound healing. Part 1: effects of silver on wound management. Wounds 2001:13(Suppl A); 4-15.

22) Schierholz JM, Lucas LJ, Rump A, Pulverer G. Efficacy of silver-coated medical devices.
J Hosp Infect 1998:40(4); 257-62.

23) Rowley N: Charting the shores of nuclear stability. Nature 1999:400; 209-211.

24) Nanotechnology: shaping the world atom by atom. NSTC Report Amate 1999, public brochure.

25) Ovington L. Nannocrystalline silver: where the old and familiar meet a new frontier.
Wounds 2001: 13; Suppl B., 5-20.

26) Yin HQ. Seven day efficacy of Acticoat dressing against multiple organisms. Fort Saskatchewan, Alberta, Canada: Westaim Biomedical Corporation; 2001. Report No: #010322.

27) Hollinger MA. Toxicological aspects of topical silver pharmaceuticals.
Crit Rev Toxicol 1996:26(3); 255-260.

28) Feng Q, Wu J, Chen G, et al: A mechanistic study of the antibacterial effect of silver ions on E. coli and S. aureus. J Biomed Mater Res. 2000:15; 602-608.

29) Richard P, LeFloch R, Chamoux C, Pannier M, Espaze E, Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiple resistant strains.
J Infect Dis 1994:170(2); 377-83.

30) Tredget EE, Shankowsky HA, Joffe AM, Inkson TI, Volpel K, Paranchych W, et. al. Epidemiology of
infections with Pseudomonas aeruginosa in burn patients: the role of hydrotherapy.
Clin Infect Dis 1992:15(6); 941-9.

31) Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT
antimicrobial barrier dressing. J Burn Care Rehabil 1999:20(3); 195-200.

32) Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am J Infect Control 1998:26(6) 572-7.

33) Coombs CJ, Wan AT, Masterton JP, Conyers RA, Pedersen J, Chia YT. Do burn patients have a silver lining? Burns 1992:18(3); 179-84.

34) Guerrero R, Menezes J, Reilly DA, Garner WL. Wound care with Acticoat in patients with non-burn skin loss. J Invest Med 2000:48(1S); 322.

35) WBP9701. Safety report for a multicenter, in-patient, matched-wound, randomized, open-label study to evaluate the safety, efficacy, quality of life benefits, and cost-effectiveness of Acticoat silver-coated dressing compared to silver sulfadiazine (1% cream) in the treatment of partial-thickness burn wounds. Alberta, Canada: Westaim Biomedical Corporation: 1998.

36) Voigt DW, Paul CN. The use of Acticoat silver impregnated telfa dressings in a regional burn and wound care center: the clinicians view. In: Wounds - A Compendium of Clinical Research and Practice. Wayne, PA: Health Management Publications Inc: 2001, pg 11-20.

37) Demling R, De Santi L: The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns 2002, In Press.

38) Grabowski B, Haney W. Characterization of silver deposits in tissue resulting from dermal application of a silver containing pharmaceutical.
J Pharm Sec 1972:61; 1788.

39) Landsdown A, Sampson B, et al.: Silver aids healing in the sterile skin wound: experimental studies in the laboratory rat. J Derm. 1977:137; 728-730.

40) Wang X, Wang N, Zhang O: Tissue deposition of silver following topical use in extensive burns. Burns 1985:11; 197-201.

41) Landsdown A: Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol 1995:25; 397-402.

42) Kirsner R, Orsted H, Wright B. Matrix metalloproteinases in normal and impaired wound healing: a potential role of nanocrystalline silver. Wounds 2001:13; suppl C; 5-15.

43) Bellinger C, Conway W. Effect of silver nitrate and sulfamylon on epithelial regeneration. Plastic Reconstr Surg 1970:45; 582-586.

44) Niedinn R: Inhibition of wound healing by antiseptics. Br J Derm 1986:115; 41-49.

45) Stern N: Silver sulfadiazine and the healing of partial thickness burns.
Br J Plastic Surg 1984:42; 581-589.

46) Deitch E, Baxter C. Failure of local immunity, a potential cause of burn wound sepsis.
Arch Surg 1985:120; 78-83.

47) Winter G: Formation of the scab and rate of epithelialization of superficial wounds in the skin.
Nature 1962:193; 293.

48) Silverman RA, Lender J, Elmets CA: Effects of occlusive and semi-occlusive dressings in the return of barrier function to trans-epidermal water loss in standardized human wounds. J Am Acad Dermatology 1989:20; 755-60.

49) Kannon G, Garrett A: Moist wound healing with occlusive dressings. Dermatol Surg 1995:21; 583.

50) Field C, Kerstein M.: Overview of wound healing in a moist environment. Am J Surg 1994:167; 2.

51) Vogt P, et al.: Dry, moist and wet skin wound repair.
Ann Plast Surg 1995:34; 493.

52) Mertz P, Eaglstein W.: The effect of a semi-occlusive dressing on the microbial population in superficial wounds. Arch Surg 1984:119; 287.

53) Davies J: Synthetic materials for covering burn wounds: progress toward
perfection. Part 1: Short term dressing material. Burns 1984:10; 94.

54) Barrick B, Campbell EJ, Owen CA.: Leukocyte proteinases in wound healing: Roles in physiologic and pathologic processes. Wound Rep Reg 1999:7; 410-422.

55) Woesnner JF Jr.: The matrix metalloproteinases family. In: Parks WC, Mecham RP (eds). Matrix metalloproteinases. San Diego, CA: Academic Press 1998:1-14.

56) Parks WC. Matrix metalloproteinases in repair. Wound Rep Reg 1999:7; 423-32.

57) Bucalo B, Eaglstein W, Falanga V.: Inhibition of cell proliferation by chronic wound fluid.
Wound Rep Reg 1993:1;181-6.

58) Wright JB, Lam K, Buret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: Effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair and Regen, In Press, 2002.

59) Wright J, Lam K, Burrell R, et al: Early healing events in a porcine model of contaminated wounds: Effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis and healing.
Wound Repair Regen in Press: 2002.

60) Tredgett EE, Shankowsky HA, Groeneveld A, Burrell R: a matched pair, randomized study evaluating
the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds.
J Burn Care Rehabil 1998:19(6)531-537.

61) Kusner R, Orsted H, Wright B.: Matrix metalloproteinases in normal and impaired wound healing: a
potential role of nanocrystalline silver: Wounds 13: supple 1-10.

62) Nealy A, Brown R.: Proteolytic activity in human burn wounds. Wound Repair Regen 1997:5; 302-308.

63) Stephens R, Silverstein P, Meites H, Jett M, Brou J. An evaluation of Acticoat dressing with regard to cost and control of infection. Wounds 2002.

64) Honari S, Gibran NS, Engrav LH, Carlson AR, Heimbach DM: Clinical benefits and cost effectiveness of Acticoat as a dressing for donor sites. Burn Care Rehab 2001: S74.

65) Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC: The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study.
Burns 2001:27(6); 621-27.

66) Munster Am.: Acticoat antimicrobial dressings and the toxic epidermonecrolysis syndrome (TENS). Baltimore, Maryland, USA: John Hopkins Bayview Medical Center.

67) Demling RH, DeSanti L. Effect of silver on wound management. Wounds 2001:14 Suppl A; 5-12.